- Home
- KLRA vs TARS Comparison
KLRA vs TARS Comparison
Compare KLRA & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$17.69
HOLD
Current Price
$58.46
Company Overview
Basic Information| Metric | KLRA | TARS |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KLRA | TARS |
|---|---|---|
| Price | $17.69 | $58.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $89.00 |
| AVG Volume (30 Days) | 864.6K | ★ 1.4M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | N/A | $56.43 |
| Revenue Next Year | N/A | $30.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $16.77 | $38.51 |
| 52 Week High | $23.82 | $85.25 |
Technical Indicators
Market Signals| Indicator | KLRA | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 32.14 | 45.13 |
| Support Level | N/A | $56.05 |
| Resistance Level | $23.82 | $67.14 |
| Average True Range (ATR) | 1.50 | 3.54 |
| MACD | -0.25 | -0.35 |
| Stochastic Oscillator | 11.47 | 23.72 |
Price Performance
Historical Comparison KLRA
TARS
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.